VUMERITY — Total Revenue
Biogen VUMERITY — Total Revenue decreased by 1.2% to $179.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.0%, from $138.80M to $179.00M. Over 3 years (FY 2022 to FY 2025), VUMERITY — Total Revenue shows an upward trend with a 10.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption or successful commercialization, while a decrease may signal increased competition or patent expiration.
Detailed definition
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product within the c...
Peer comparison
Standard revenue reporting for individual pharmaceutical products across all major biotech and pharma companies.
biib_segment_vumerity_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $90.90M | $120.90M | $128.00M | $136.80M | $137.80M | $150.80M | $108.20M | $146.20M | $165.50M | $156.40M | $127.50M | $165.80M | $158.10M | $176.60M | $138.80M | $212.30M | $214.60M | $181.10M | $179.00M |
| QoQ Change | — | +33.0% | +5.9% | +6.9% | +0.7% | +9.4% | -28.2% | +35.1% | +13.2% | -5.5% | -18.5% | +30.0% | -4.6% | +11.7% | -21.4% | +53.0% | +1.1% | -15.6% | -1.2% |
| YoY Change | — | — | — | +50.5% | +14.0% | — | -15.5% | +6.9% | +20.1% | +3.7% | +17.8% | +13.4% | -4.5% | +12.9% | +8.9% | +28.0% | +35.7% | +2.5% | +29.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's vumerity — total revenue?
- Biogen (BIIB) reported vumerity — total revenue of $179.00M in Q1 2026.
- How has Biogen's vumerity — total revenue changed year-over-year?
- Biogen's vumerity — total revenue increased by 29.0% year-over-year, from $138.80M to $179.00M.
- What is the long-term trend for Biogen's vumerity — total revenue?
- Over 3 years (2022 to 2025), Biogen's vumerity — total revenue has grown at a 10.5% compound annual growth rate (CAGR), from $553.40M to $746.80M.
- What does vumerity — total revenue mean?
- The total sales revenue generated by a specific pharmaceutical product.